The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 21, 2025
Filed:
Jul. 04, 2023
Applicant:
Takeda Pharmaceutical Company Limited, Osaka, JP;
Inventors:
Tatsuhiko Fujimoto, Fujisawa, JP;
Kentaro Rikimaru, Fujisawa, JP;
Koichiro Fukuda, Fujisawa, JP;
Hiromichi Sugimoto, Tokyo, JP;
Takahiro Matsumoto, Fujisawa, JP;
Norihito Tokunaga, Fujisawa, JP;
Mariko Hirozane, Fujisawa, JP;
Assignee:
Takeda Pharmaceutical Company Limited, Osaka, JP;
Primary Examiner:
Int. Cl.
CPC ...
C07D 213/61 (2005.12); A61P 25/00 (2005.12); C07D 211/24 (2005.12); C07D 211/36 (2005.12); C07D 211/56 (2005.12); C07D 213/30 (2005.12); C07D 213/74 (2005.12); C07D 213/75 (2005.12); C07D 215/44 (2005.12); C07D 401/06 (2005.12); C07D 401/12 (2005.12); C07D 401/14 (2005.12); C07D 405/06 (2005.12); C07D 405/12 (2005.12); C07D 405/14 (2005.12); C07D 409/06 (2005.12); C07D 409/12 (2005.12); C07D 413/06 (2005.12); C07D 417/06 (2005.12); C07D 417/14 (2005.12);
U.S. Cl.
CPC ...
C07D 211/24 (2012.12); A61P 25/00 (2017.12); C07D 211/36 (2012.12); C07D 211/56 (2012.12); C07D 213/30 (2012.12); C07D 213/61 (2012.12); C07D 213/74 (2012.12); C07D 213/75 (2012.12); C07D 215/44 (2012.12); C07D 401/06 (2012.12); C07D 401/12 (2012.12); C07D 401/14 (2012.12); C07D 405/06 (2012.12); C07D 405/12 (2012.12); C07D 405/14 (2012.12); C07D 409/06 (2012.12); C07D 409/12 (2012.12); C07D 413/06 (2012.12); C07D 417/06 (2012.12); C07D 417/14 (2012.12);
Abstract
Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.